The panel discusses unmet needs in the treatment landscape for patients with cervical cancer and the importance of clinical trials.
When I had my breast biopsy prior to my second diagnosis, it was my first time to experience a biopsy. That’s because the first experience was atypical and ...
There was an ORR of 58% observed with Keytruda plus Keytruda, which exceeded the targeted ORR of 40%. The treatment combination of Keytruda (pembrolizumab) ...
Cancer is the most complex health challenge we face. There are more than 200 different types of it, for a start; and even that might be putting it too ...
An artificial intelligence model showed promise in predicting ovarian cancer outcomes.An artificial intelligence model called IRON (Integrated Radiogenomics ...
The utilization of palliative care shows low occurrence for patients with de novo metastatic breast cancer (dnMBC) alongside a lack of fairness in ...
When speaking to cancer with patients, don't tell them how someone else has it worse off. Like many people with blood cancer, my diagnosis came in a rather ...
Of the estimated 16,000 patients in the U.S. diagnosed with MDS every year, approximately 3.6% of them have an IDH1 mutation.The recent approval of Tibsovo ...
For many, these are such happy, carefree times; but when you’re battling cancer, these interactions can become a bit more complicated. People, with good ...
The recent Food and Drug Administration (FDA) approval of Fruzaqla (frutquitinib) for patients with pretreated metastatic colorectal cancer (mCRC) led to ...
The end of the year typically brings a number of FDA approvals, and 2023 is no different. Last week, the Food and Drug Administration approved a new drug, ...
Stephen Bradley is a GP, NIHR Academic Clinical Lecturer at the University of Leeds and clinical lead for cancer in the Leeds office of the West ...